# Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

Study · id `cardio:ct-nct03315143` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03315143](<https://clinicaltrials.gov/study/NCT03315143>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03315143

Browse, organ or system: Heart; Kidneys; Metabolism  
Browse, condition area: Heart failure; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 10584 participants.

## Technical summary

Registry record NCT03315143. Randomized; quadruple masking; primary purpose prevention. Start 2017-12-19 (actual); primary completion 2020-07-08 (actual). Results posted on 2022-10-28.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 10584 participants (enrolled count; ClinicalTrials.gov record NCT03315143, source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)
- Started: 2017-12-19 (actual) (ClinicalTrials.gov record NCT03315143, source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)
- Primary completion: 2020-07-08 (actual) (ClinicalTrials.gov record NCT03315143, source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)
- Completion: 2020-07-08 (actual) (ClinicalTrials.gov record NCT03315143, source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)
- Results first posted: 2022-10-28 (ClinicalTrials.gov record NCT03315143, source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Chile; China; Czechia; Denmark; Estonia; France; Georgia; Germany; Greece; Guatemala; Hungary; India; Israel; Italy; Latvia; Lithuania; Mexico; Netherlands; New Zealand; North Macedonia; Norway; Peru; Poland; Portugal; Puerto Rico; Romania; Russia; Serbia; Slovakia; South Africa; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT03315143, source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03315143-2022-10-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
- Acronym: SCORED
- Condition: Heart Failure
- Condition: Type 2 Diabetes Mellitus
- Condition: Chronic Kidney Diseases
- Intervention (Drug): Sotagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Lexicon Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Sanofi
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Lexicon Pharmaceuticals (`cardio:org-lexicon-pharmaceuticals`)
- Registry lists this organization as a collaborator: Sanofi (`cardio:org-sanofi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (`cardio:pubmed-33200891`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial (`cardio:pubmed-38277468`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial (`cardio:pubmed-39961315`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7761ea7e8a701129f22c282e3b46dbb62ee80f31c7aa9fd05f342d5a00478c88
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
